A Phase 3 interventional study of Baricitinib and Tocilizumab in Systemic Juvenile Idiopathic Arthritis, sponsored by Eli Lilly and Company. Active, not recruiting at 55 sites in 14 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Arthritis, Juvenile with a site in Italy — 20 open to participants now, 24 under way, 11 of them phase 3. Arthritis, Juvenile · Italy.
Among the 56 studies in Arthritis, Juvenile with a site in Italy, this one is the 29th largest by planned enrollment of the 43 interventional ones that give a count, is one of 2 that started in 2020, is one of 28 in phase 3, reaches primary completion later than 8 of the 23 other live ones, and was the 34th registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.
Browse Arthritis, Juvenile studies →20 of the 56 studies in Arthritis, Juvenile with a site in Italy are open now. Recruiting first, the newest first:
Alfasigma S.p.A. · Sites in Italy, Belgium, Czechia and 6 more countries
Ages 8–18
Duke University · Sites in Italy, United States, Germany and 1 more country
Ages 2–21
Novartis Pharmaceuticals · Sites in Italy, United States, Canada and 5 more countries
Ages 1+
Bristol-Myers Squibb · Sites in Italy, United States, Brazil and 8 more countries
Ages 5–17
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 6–18
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 1 Year to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 28 · Phase 4 2
First in 2000; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 58 is above the median of 52 across 230 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 90 across the 43 interventional studies, 130 across the 13 observational. Of the 30 that completed or were terminated, 20 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 56 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 4 studies filed under Arthritis, Juvenile — fewer than ten, so there is no comparison to draw.
3 of the studies in Arthritis, Juvenile with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07554495Phase 3Alfasigma S.p.A.Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents | 2027-06 |
| NCT06618937Istituto Giannina GasliniToward Personalized Medicine to Guide Drug Withdrawal in Children with Juvenile Idiopathic Arthritis in Clinical Remission | 2027-01-01 |
| NCT07203001Novartis PharmaceuticalsA Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease | 2027-04-22 |
Add all 3 to your calendar (.ics) → With an account.
Among the 56 studies in Arthritis, Juvenile with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA). Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive baricitinib or tocilizumab reference. In cohort 2, participants will receive baricitinib.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Baricitinib given orally.
Drug: Baricitinib
Tocilizumab given Subcutaneously (SC).
Drug: Tocilizumab
Baricitinib given orally.
Drug: Baricitinib
Administered orally
Also known as: LY3009104
Administered SC
Percentage of Participants Achieving Adapted Pediatric American College of Rheumatology 30 Responder Index (PediACR30) Response Criteria at Week 12
Percentage of Participants Achieving Adapted PediACR30 Response Criteria
Time frame: Week 12
Percentage of Participants Achieving Adapted PediACR30 Response Criteria at Week 24
Percentage of Participants Achieving Adapted PediACR30 Response Criteria
Time frame: Week 24
Percentage of Participants with Inactive Disease
Percentage of Participants with Inactive Disease
Time frame: Week 12
Percentage of Participants with Minimal Disease Activity
Percentage of Participants with Minimal Disease Activity
Time frame: Week 12
Change from Baseline in Juvenile Arthritis Disease Activity Score (JADAS)-27
Change from Baseline in JADAS-27
Time frame: Baseline, Week 24
Change from Baseline in Arthritis-Related Pain Severity as Measured by the Childhood Health Assessment Questionnaire (CHAQ) Pain Visual Analog Scale (VAS) Item
Change from Baseline in Arthritis-Related Pain Severity as Measured by the CHAQ Pain VAS Item
Time frame: Baseline, Week 24
Pharmacokinetics (PK): Maximum Plasma Baricitinib Concentration at Steady-State (Cmax, ss)
PK: Cmax, ss of Baricitinib
Time frame: Baseline through Week 24
PK: Area Under the Baricitinib Concentration-Time Curve at Steady-State (AUC, ss)
PK: AUC, ss of Baricitinib
Time frame: Baseline through Week 24
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · www.vivli.org
Started Feb 2020 (actual). Primary completion is estimated for Oct 2026, 80 months after the start.
Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's planned 80 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib